1. Home
  2. TECX vs GEVO Comparison

TECX vs GEVO Comparison

Compare TECX & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • GEVO
  • Stock Information
  • Founded
  • TECX 2019
  • GEVO 2005
  • Country
  • TECX United States
  • GEVO United States
  • Employees
  • TECX N/A
  • GEVO N/A
  • Industry
  • TECX
  • GEVO Major Chemicals
  • Sector
  • TECX
  • GEVO Industrials
  • Exchange
  • TECX Nasdaq
  • GEVO Nasdaq
  • Market Cap
  • TECX 387.1M
  • GEVO 418.4M
  • IPO Year
  • TECX 2018
  • GEVO 2011
  • Fundamental
  • Price
  • TECX $16.80
  • GEVO $1.67
  • Analyst Decision
  • TECX Buy
  • GEVO Buy
  • Analyst Count
  • TECX 6
  • GEVO 2
  • Target Price
  • TECX $79.17
  • GEVO $7.58
  • AVG Volume (30 Days)
  • TECX 443.3K
  • GEVO 9.5M
  • Earning Date
  • TECX 11-06-2025
  • GEVO 11-06-2025
  • Dividend Yield
  • TECX N/A
  • GEVO N/A
  • EPS Growth
  • TECX N/A
  • GEVO N/A
  • EPS
  • TECX N/A
  • GEVO N/A
  • Revenue
  • TECX N/A
  • GEVO $80,187,000.00
  • Revenue This Year
  • TECX N/A
  • GEVO $909.99
  • Revenue Next Year
  • TECX N/A
  • GEVO $22.37
  • P/E Ratio
  • TECX N/A
  • GEVO N/A
  • Revenue Growth
  • TECX N/A
  • GEVO 341.75
  • 52 Week Low
  • TECX $13.70
  • GEVO $0.67
  • 52 Week High
  • TECX $61.07
  • GEVO $3.39
  • Technical
  • Relative Strength Index (RSI)
  • TECX 33.64
  • GEVO 53.71
  • Support Level
  • TECX $15.34
  • GEVO $1.54
  • Resistance Level
  • TECX $18.61
  • GEVO $1.80
  • Average True Range (ATR)
  • TECX 1.71
  • GEVO 0.10
  • MACD
  • TECX -1.06
  • GEVO -0.02
  • Stochastic Oscillator
  • TECX 12.18
  • GEVO 40.62

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About GEVO Gevo Inc.

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.

Share on Social Networks: